Cromsource adds new CMO, expands medical affairs offering

Italy-based CRO Cromsource has appointed Pfizer, Novartis and Paraxel vet Dr. Grzegorz Rychlik as its new chief medical officer as it beefs up its medical affairs department.

Dr. Rychlik, who has more than a quarter of a century of biopharma experience under his belt, has worked across a number of big and small biopharmas as a medical director and CMO, and most recently was the managing director of U.K.-based MRCD Pharma Services.

Dr. Oriana Zerbini, founder and CEO of Cromsource, said: “The addition of an experienced and respected medical professional such as Greg strongly positions Cromsource to be able to further support the increasingly complex product development needs of our clients. Additionally, as we expand our medical affairs offering we will optimize and grow our consultancy and medical services to better serve our clients.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Dr. Troy McCall, the company’s COO, added that under their new CMO’s tenure, they will expand the company's medical monitoring, pharmacovigilance, and medical writing services “to meet growing client needs.”

He went on: “Having highly experienced and skilled individuals such as Greg within the Medical Affairs Services group will allow for the optimization and standardization of interdependent processes, while leveraging efficiencies and ensuring that the highest level of quality is delivered.”

This forms part of its broader expansion plans over the years that also saw it back in May make a glut of new appointments to its management team, as it also opened a new office in CRO heartland Research Triangle Park.

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.